Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VERU-722
- Development stage
- Discontinued
- Lead developer
- Veru
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VERU-722 (formerly MSS-722) is an oral selective estrogen receptor modulator (SERM) developed for the treatment of male infertility, specifically targeting men with secondary hypogonadism. By antagonizing estrogen receptors in the hypothalamus and pituitary gland, the drug aims to increase the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulates natural testosterone production and spermatogenesis in the testes. The asset was acquired by Veru Inc. (formerly The Female Health Company) through its merger with Aspen Park Pharmaceuticals in 2016. While initially a key part of the company's urology pipeline and planned for Phase 2 clinical development, the program has since been deprioritized as Veru shifted its strategic focus toward oncology and other therapeutic areas.
- Other names
- MSS-722MSS722MSS 722
02
Targets
ER (Estrogen receptor)
Beyond the preview
Go deeper on VERU-722.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VERU-722.